Merck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule

An experimental antibody-drug conjugate from Merck and China-based Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline victory as it approaches the patent cliff for its best-selling ...